News» Go to news main
How Dalhousie has played a key role in Nova Scotia's vaccination efforts
When the first doses of the COVID-19 vaccine arrived in Nova Scotia on December 15th, 2020, it was a milestone day for the province that offered the first optimistic glimpse of life after COVID-19.
The vaccine rollout is expected to take several months. The method involves a phased approach that first prioritizes delivering vaccines to healthcare workers who are directly involved in the front-line COVID response. However, before anyone rolled up their sleeves, the province needed to solve a seemingly simple question: Where would the vaccine be stored?
The Pfizer-BioNTech COVID-19, one of the two vaccines being used in Nova Scotia, must be stored in an ultra-cold freezer at temperatures between -80°C and -60°C. For perspective, the coldest temperature ever recorded in Canada was -63 °C in Snag, Yukon back in 1947. With provinces across the country scrambling to procure freezers that could meet these requirements, the government of Nova Scotia turned to the Life Sciences Research Institute (LSRI) at Dalhousie University to be one of Nova Scotia’s ten cold storage sites.
A quick turnaround
Dr. Roger McLeod, Associate Dean of Research for the Faculty of Medicine, remembers checking his email on December 1, 2020, to learn that planning was underway to receive the first test shipment in only one week.
While in fact several labs in the medical school’s Tupper Building and LSRI are equipped with an ultra-cold freezer, many of them were already being used for critical and time-sensitive research projects. Despite this, Dr. McLeod points to the research community’s selflessness as he worked through the process of finding a freezer.
“All of the researchers involved have been very helpful and understood how important this was,” says Dr. McLeod. “Credit to the researchers for being so accommodating. A lot of them even offered the freezers in their own labs.”
After a long day of gathering information and taking stock of what was available, it was determined that a vacant lab in the LSRI had a freezer that met the exact requirements and could store over 100,000 doses of the vaccine. Not only did the freezer satisfy the storage demands, but it was also attached to backup generators and located close to two hospitals, making it the ideal location for a vaccination clinic.
A plan for everything
After securing the site, Dr. McLeod tapped Building Services Manager, Paul Bourgeois, to oversee the logistics of effective storage and continuous temperature monitoring of the vaccine.
“Things were moving in a hurry,” Bourgeois recalled.
Before the vaccine could be shipped, both he and Dr. McLeod were required to complete webinars provided by the Public Health Agency of Canada (PHAC) and Pfizer on how to properly handle and receive the vaccine.
“It’s pretty amazing how quickly PHAC rolled out the teaching materials at every level,” says Dr. McLeod. “It’s been very comprehensive to make sure people are well informed and educated about the vaccine.”
The vaccine is shipped around the world in a specially designed, temperature-controlled thermal container that uses dry ice to maintain the recommended storage temperature conditions.
“There is a device inside every container that monitors the temperature 24 hours a day,” says Bourgeois. “When we open the container and stop the temperature recorder, we get an indicator that the shipment has maintained the proper ultra –low temperature throughout its journey from Belgium to us here in Halifax.”
Once the vaccine is unpacked and safely stored in the ultra-cold freezer, there is also a procedure to send the expensive shipping container back to Pfizer to be reused for a future shipment.
“We take the dry ice out and a lot of times we give it to different researchers who can use it their labs,” says Bourgeois. “That’s been one of the added benefits.”
Experience of a lifetime
With news of Nova Scotia receiving its largest shipments of the COVID-19 vaccine to date, and larger shipments expected, the handling and storage of the vaccine has become a well-oiled machine, one that was recognized by then Minister of Health and Wellness, the Honourable Leo Glavine in a letter to Dalhousie President, Dr. Deep Saini.
In the letter, Minister Glavine specifically highlighted the exceptional work of Dr. David Anderson, Dean of the Faculty of Medicine, Dr. McLeod, and Mr. Bourgeois, for their willingness to allow the LSRI to be used to store the vaccine, noting that “This single act brought hope to Nova Scotians that COVID-19 would come to an end.”
For Bourgeois, playing a role in ending a global pandemic was the furthest thing from his mind when he got word back in December that Dalhousie would be storing the vaccine.
“I’m really glad I had the opportunity to go through this. There have been some challenges, but it’s been rewarding and I’m just really happy to be involved,” says Bourgeois. “It’s pretty cool.”
- Doctor for a Day at DMNB returns for a fourth time in virtual workshop
- DAL EMBRACES BLACK STUDIES RESEARCH WITH NEW UNIVERSITY‑WIDE INSTITUTE
- World‑leading geriatrician and anti‑ageism campaigner wins the Ryman Prize
- Locally Developed Cancer Program to Become Standard of Care Throughout Atlantic Canada
- The omicron variant: Dal experts share what we know so far about the new COVID variant
- 2021 Discovery Awards celebrate the career of a Dal research icon and a new generation of leaders
- More research and resources needed to better support women left homeless due to intimate partner violence: Dalhousie study
- Tackling Anti‑Black Racism in Health Care and Education: National Research Collaborative Takes Action